Jasper Therapeutics, Inc. - Class A

The momentum for this stock is not very good. Jasper Therapeutics, Inc. - Class A is a mediocre stock to choose.

News

JMP Securities Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Ticker Report Stock analysts at JMP Securities started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The...\n more…

Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at JMP Securities

Zolmax Equities researchers at JMP Securities began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) in a report issued on Monday, MarketBeat.com reports. The brokerage set an...\n more…

Cantor Fitzgerald Reiterates "Overweight" Rating for Jasper Therapeutics (NASDAQ:JSPR)

Ticker Report Jasper Therapeutics (NASDAQ:JSPR - Get Free Report)s stock had its "overweight" rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports...\n more…

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Globe Newswire REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...\n more…

Jasper Therapeutics (NASDAQ:JSPR) Receives Overweight Rating from Cantor Fitzgerald

Zolmax Cantor Fitzgerald reaffirmed their overweight rating on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a research report report published on Monday morning, Benzinga reports.\nSeveral...\n more…

Jasper Therapeutics initiated with bullish view at JMP Securities, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…